Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: A secondary analysis of the VIBRANT study - Abstract

In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer).

Written by:
Gollar KM, Young DG, Bailen J, He W, Forero-Schwanhaeuser S. Are you the author?
Metropolitan Urology, Jeffersonville, IN, USA.

Reference: Urol Nurs. 2012 Jan-Feb;32(1):38-46, 50.

PubMed Abstract
PMID: 22474864

UroToday.com Overactive Bladder (OAB) Section